OMERS ADMINISTRATION Corp Purchases Shares of 84,750 Boston Scientific Corporation $BSX

OMERS ADMINISTRATION Corp acquired a new stake in shares of Boston Scientific Corporation (NYSE:BSX) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 84,750 shares of the medical equipment provider’s stock, valued at approximately $3,617,000.

A number of other institutional investors and hedge funds have also made changes to their positions in BSX. BlackRock Inc. acquired a new position in Boston Scientific in the second quarter valued at $5,534,781,000. State Street Corp raised its holdings in shares of Boston Scientific by 1.4% in the 4th quarter. State Street Corp now owns 65,846,059 shares of the medical equipment provider’s stock worth $6,278,422,000 after purchasing an additional 920,495 shares during the period. Capital World Investors lifted its stake in shares of Boston Scientific by 1.9% in the 4th quarter. Capital World Investors now owns 27,151,575 shares of the medical equipment provider’s stock valued at $2,588,953,000 after purchasing an additional 502,627 shares in the last quarter. Norges Bank acquired a new position in shares of Boston Scientific in the 4th quarter valued at about $2,199,395,000. Finally, Morgan Stanley grew its holdings in shares of Boston Scientific by 10.8% during the 4th quarter. Morgan Stanley now owns 22,960,556 shares of the medical equipment provider’s stock worth $2,189,289,000 after purchasing an additional 2,246,308 shares during the period. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Stock Up 1.7%

NYSE BSX opened at $49.86 on Wednesday. The stock has a market cap of $72.26 billion, a PE ratio of 20.19, a P/E/G ratio of 1.07 and a beta of 0.56. Boston Scientific Corporation has a fifty-two week low of $42.20 and a fifty-two week high of $109.50. The business has a 50 day moving average price of $46.44 and a two-hundred day moving average price of $57.14. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The company had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. During the same quarter last year, the company earned $0.75 earnings per share. Boston Scientific’s revenue for the quarter was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, sell-side analysts predict that Boston Scientific Corporation will post 3.3 EPS for the current fiscal year.

Boston Scientific announced that its board has initiated a stock repurchase program on Monday, May 18th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the medical equipment provider to repurchase up to 6.4% of its stock through open market purchases. Stock buyback programs are generally a sign that the company’s leadership believes its shares are undervalued.

Insider Activity at Boston Scientific

In other news, Director David C. Habiger acquired 2,100 shares of the firm’s stock in a transaction on Wednesday, August 5th. The stock was bought at an average cost of $47.59 per share, with a total value of $99,939.00. Following the transaction, the director directly owned 17,160 shares in the company, valued at approximately $816,644.40. This represents a 13.94% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Edward J. Ludwig bought 5,000 shares of the stock in a transaction dated Friday, July 31st. The shares were acquired at an average price of $45.48 per share, with a total value of $227,400.00. Following the completion of the purchase, the director directly owned 30,359 shares of the company’s stock, valued at approximately $1,380,727.32. This represents a 19.72% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last three months, insiders bought 194,522 shares of company stock valued at $9,385,210. Corporate insiders own 0.34% of the company’s stock.

Wall Street Analyst Weigh In

BSX has been the topic of several research reports. Raymond James Financial restated an “outperform” rating and issued a $57.00 price target on shares of Boston Scientific in a report on Thursday, July 30th. Bank of America decreased their price objective on shares of Boston Scientific from $105.00 to $68.00 and set a “buy” rating for the company in a research note on Monday, May 18th. Jefferies Financial Group dropped their price objective on shares of Boston Scientific from $100.00 to $67.00 and set a “buy” rating for the company in a research report on Wednesday, June 24th. Canaccord Genuity Group cut their target price on shares of Boston Scientific from $70.00 to $66.00 and set a “buy” rating on the stock in a research note on Thursday, July 30th. Finally, Evercore set a $65.00 target price on shares of Boston Scientific in a report on Monday, July 6th. Twenty-four investment analysts have rated the stock with a Buy rating, five have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Boston Scientific presently has an average rating of “Moderate Buy” and an average target price of $71.62.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.